Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

B. Weinstock-Guttman, S.L. Galetta, G. Giovannoni, E. Havrdova, M. Hutchinson, L. Kappos, P.W. O'Connor, J.T. Phillips, C.H. Polman, W.H. Stuart, F. Lynn, C. Hotermans

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)898-905
JournalJournal of Neurology
Volume259
Issue number5
DOIs
Publication statusPublished - 2012

Cite this

Weinstock-Guttman, B., Galetta, S. L., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., ... Hotermans, C. (2012). Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 259(5), 898-905. https://doi.org/10.1007/s00415-011-6275-7